From August 2021 Biological E to begin producing 75-80 million doses of vaccine candidate

From August 2021, vaccine manufacturer Biological E is preparing to produce 75-80 million doses per month of its recombinant protein vaccine candidate.

The company also said its vaccine is going to be one of the most affordable vaccines available in India.

Biological E MD, Mahima Datla said, as she is not at liberty to share details of vaccine pricing but I can assure you it will be one of the most affordable Covid-19 vaccines available in India. She further assured that the company “will not take advantage of the situation.”

She also added we are the third generation in the vaccine manufacturing business. COVID didn’t make us enter into this business. We have made vaccines accessible in pre-pandemic times also to the countries that needed them the most.

Biological E also signed to manufacture 600 million doses of Johnson & Johnson single jab covid vaccine in India. ‘

Mahima Datla’s statement comes at a time when India is fighting with the second wave of the coronavirus pandemic and the cases in India have skyrocketed, claimed many lives and the country’s healthcare system has been crippled in saving lives.

Further, Russia has also announced emergency use of its single-shot jab Sputnik Light that will also be manufactured in India among other countries. If Biological E’s candidate vaccine and its plans get approval, it would strengthen India’s vaccine list. At present, India has three vaccines- Covishield by SII, COVAXIN by Bharat Biotech, and Russia’s Sputnik V produced by Dr. Reddy’s and ease shortage across healthcare facilities.

Mahima Datla is confident enough that they will be able to produce 75-80 million doses per month right from the start.

She also added, “We have confidence in our production capabilities and will be able to deliver the number from August onwards. We are well resourced in terms of capacities, both for bulk-antigen and fill-finish.” The company is also in the preparation phase for its phase III trials on 1,268 volunteers between the age brackets of 18-50 at 15 centers as part of its global study. Biological E will begin its trial in August 2021.

Do read: Importance of US statement of waiving patent on the covid vaccine